Pulse Biosciences, Inc. (NASDAQ:PLSE) Sees Large Decrease in Short Interest

Pulse Biosciences, Inc. (NASDAQ:PLSE) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 2,080,000 shares, a drop of 18.1% from the October 31st total of 2,540,000 shares. Based on an average trading volume of 169,800 shares, the days-to-cover ratio is currently 12.2 days. Approximately 12.2% of the shares of the company are sold short.

Pulse Biosciences Stock Performance

NASDAQ:PLSE traded up $1.03 during mid-day trading on Friday, hitting $21.40. The company’s stock had a trading volume of 123,050 shares, compared to its average volume of 202,033. Pulse Biosciences has a fifty-two week low of $6.59 and a fifty-two week high of $22.69. The stock has a fifty day moving average of $17.31 and a 200-day moving average of $15.77.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the company posted ($0.19) earnings per share.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Wednesday.

Institutional Investors Weigh In On Pulse Biosciences

Large investors have recently made changes to their positions in the company. Franklin Resources Inc. bought a new stake in Pulse Biosciences during the 3rd quarter worth approximately $378,000. Barclays PLC boosted its stake in Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after purchasing an additional 23,738 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares during the last quarter. State Street Corp increased its stake in shares of Pulse Biosciences by 17.8% in the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after buying an additional 69,696 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Pulse Biosciences in the third quarter valued at $588,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.